Loading..

Vaxart, Inc. - Shareholder/Analyst Call

2022-06-16 20:07:00

To provide an overview of the Company’s oral vaccine programs

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

2022-06-03 12:00:00

Vaxart, Inc. reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant. "Approved COVID-19 vaccines afford less protection against infection from new SARS-CoV-2 variants compared with the original parental strain against which they were developed. A broadly cross-reactive vaccine may be the most effective way to protect against current and future variants. The data reported are from a study in which the S-only Wuhan and Omicron vaccine candidates were compared in a hamster challenge model. Animals were immunized mucosally on days zero and 28 and challenged on day 56 with an Omicron varia of SARS-CoV-2-2. Both vaccines produced antibody responses to the S protein of Omicron, with the Omicron candidate slightly better at making serum IgG antibodies to the matched protein. Weight loss, lung viral titers, and viral shedding were reduced in animals receiving either vaccine candidate compared to unvaccinated animals. These findings demonstrate that in this preclinical model both vaccine candidates protect against the Omicron variant.t. Earlier this year, Vaxart announced that data from its non-human primate study showed that the S-only candidate generated antibodies to the original COVID-19 Wuhan strain and those antibodies also react strongly with the Beta, Delta, Alpha and Gamma variants of SARS-CoV-2 in the serum and nasal mucosa of non-human primates.

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

2022-06-02 12:30:00

Vaxart reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candidate in subjects aged 55 – 80 years (NCT04854746). Results of the trial show a robust immune response across all doses, with a dose-dependent production of IgA antibody secreting cells (ASCs), consistent with previous studies conducted in younger populations. The results also demonstrate that the vaccine candidate was well tolerated with a favorable safety profile. These data support the continued development of Vaxart’s oral norovirus vaccine candidate in adult populations, including elderly adults, and add to the growing body of evidence supporting its clinical utility. Vaxart is conducting a Phase 2 clinical challenge study of its norovirus vaccine candidate in adult volunteers. Norovirus is the leading cause of acute gastroenteritis that produces vomiting and diarrhea among people of all ages. The World Health Organization’s (WHO) Product Development for Vaccines Advisory Committee has identified norovirus as a priority disease for vaccine development. The virus causes up to 21 million cases, 109,000 hospitalizations and 900 deaths annually in the United States. Adults over the age of 65 years are especially vulnerable to norovirus infection, with 7.5% of this population infected annually. Norovirus also has a negative health economic impact, which has been estimated to cost $10.6 billion annually in the United States alone. Key findings from the Phase 1b study in elderly patients include: Robust immune response across all doses, with a dose dependent IgA ASC response IgA ASC responses were consistent with previous studies in younger subjects All solicited adverse events were mild or moderate with generally similar rates of events between the vaccine groups and placebo Vaxart is also reporting preliminary data from a Phase 1 boosting regimen of its norovirus vaccine candidate. These data show that the candidate was able to successfully boost antibody responses, with antibody responses trending better with administration spread out over 3 months versus a shorter interval. Vaxart has previously reported that booster administration at a year post first dose was able to return antibody titers to levels similar to what was observed after the first dose.

Vaxart, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:30 AM

2022-06-02 12:00:00

Vaxart, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:30 AM. Venue: Marriott Marquis, New York City, New York, United States.

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

2022-05-19 12:30:00

Vaxart’s (NASDAQ: VXRT) S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2. The report also described updated results from Vaxart’s Phase I clinical trial that suggest Vaxart’s other vaccine candidate, the one targeting both the S and N proteins, could be effective against a range of diverse coronaviruses. The study compared various measures of immunity and viral shedding in hamster cohorts immunized with Vaxart’s S-only vaccine candidate (administered orally and intranasally), an intramuscular protein vaccine control and placebo. The vaccinated hamsters were then infected with high doses of SARS-CoV-2 to create vaccine breakthrough and exposed to naïve animals during the breakthrough period. The study authors concluded that Vaxart’s S-only construct “reduced disease and decreased airborne transmission in a hamster model.” The publication also reported results from the Phase I clinical study of Vaxart’s S+N vaccine candidate showing that it stimulated SARS-CoV-2-specific IgA antibodies in saliva and nasal samples from human subjects and was cross-reactive to many different coronaviruses that are more divergent than circulating variants of SARS-CoV-2. The S-only data from the hamster transmission preclinical study was initially reported last October in the non-peer reviewed journal bioRxiv. Vaxart first reported the potential cross-reactive properties of its S+N vaccine candidate in May 2021. The new Science Translational Medicine publication includes additional detail regarding IgA antibody responses in human subjects. Vaxart has moved to Phase II clinical trials with the S-only vaccine candidate and expects to report those results later this year. Vaxart has also completed and published preliminary Phase I results from its S+N vaccine candidate. As previously stated, the company plans to compare the S-only and S+N vaccine candidates and to decide which approach offers the best way forward for its COVID-19 vaccine development program, particularly in the face of emerging variant strains.

Vaxart, Inc. Announces CFO Changes

2022-05-11 21:28:00

On May 10, 2022, Vaxart, Inc. (the “Company”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“FLG Partners”), a chief financial officer services and board advisory consulting firm, as the Company’s Interim Chief Financial Officer and, in his capacity as a non-employee consultant, as the Company’s Principal Financial Officer while Vaxart conducts its ongoing search for a Chief Financial Officer. As of May 10, 2022, Andrei Floroiu ceased to serve as the Company’s Principal Financial Officer and Margaret Echerd ceased to serve as the Company’s Principal Accounting Officer. Mr. Ahmad has served as the Interim Chief Financial Officer of IRIDEX Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, since November 2020.

Vaxart, Inc. Announces Management Changes

2022-05-11 21:28:00

On May 10, 2022, Vaxart, Inc. (the “Company”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“FLG Partners”), in his capacity as a non-employee consultant and as the Principal Accounting Officer. As of May 10, 2022, Margaret Echerd ceased to serve as the Company’s Principal Accounting Officer. Mr. Ahmad has served as the Interim Chief Financial Officer of IRIDEX Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, since November 2020. As previously disclosed, on March 28, 2022, Ms. Echerd notified Company that she intended to retire as Senior Vice President and Principal Accounting Officer, effective as of May 5, 2022. Subsequently, Ms. Echerd agreed to delay her retirement until May 11, 2022.

Vaxart, Inc. Proposes Amendment to Restated Certificate of Incorporation

2022-04-28 20:04:00

Vaxart, Inc. proposed amendment to Restated Certificate of Incorporation to increase the authorized number of shares of common stock to 250,000,000 shares. in its AGM to be held on June 7, 2022.

Vaxart, Inc. Presents at World Vaccine Congress 2022, Apr-20-2022 03:55 PM

2022-04-16 13:52:00

Vaxart, Inc. Presents at World Vaccine Congress 2022, Apr-20-2022 03:55 PM. Venue: Marriott Marquis Washington, Washington , District Of Columbia, United States. Speakers: Sean N. Tucker, Senior VP & Chief Scientific Officer.

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

2022-03-31 20:12:00

On March 28, 2022, Margaret Echerd notified Vaxart, Inc. that she intends to retire as Senior Vice President and Principal Accounting Officer, effective as of May 5, 2022.

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022

2022-01-27 09:13:00

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022. Venue: Marriott Marquis Washington, Washington , District Of Columbia, United States.

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

2021-12-16 13:00:00

Vaxart, Inc. said it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month. In the second study, Vaxart will conduct an animal Omicron challenge study to assess how its current Phase II COVID-19 vaccine candidate performs in comparison to an Omicron-specific vaccine candidate that Vaxart is developing. Vaxartdeliberately engineered its COVID-19 vaccine candidate to be cross-reactive against emerging variants based on Vaxart scientists’ early recognition of the risk of emerging variants of SARS-CoV-2. In May 2021, the Company announced Phase I clinical test results demonstrating that its vaccine candidate, VXA-CoV2-1, produced broad cross-reactive T cell and IgA responses against other, non-COVID coronaviruses. Injectable vaccines primarily stimulate serum IgG responses, but Vaxart’s COVID-19 vaccine candidate has been shown to trigger mucosal IgA in the nose, mouth and lungs, where SARS-CoV-2 infection occurs. Mucosal IgA antibodies contain four or more antigen-binding sites, while IgG antibodies contain only two.

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

2021-12-01 00:00:00

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc. on November 30, 2021. Vaxart, Inc. (NasdaqCM:VXRT) agreed to the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility. Vaxart expects the facility to be operational for GMP production in Q1 2022. Vaxart, Inc. (NasdaqCM:VXRT) completed the acquisition of KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc. on November 30, 2021.

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart, Inc

2021-11-18 21:02:00

A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc., had cellular correlates of protection against influenza infection. These cellular correlates were found using mass cytometry analysis of vaccine-elicited cellular immune responses in the peripheral blood of participants in a previously reported Phase II H1N1 challenge study of VXA-A1.1. The U.S. Centers for Disease Control and Prevention (CDC) estimates that, on average, 36,000 people in the U.S. died from the flu in each of the past ten years. It is estimated that 61,000 people in the U.S. died from the flu in the 2017-2018 season – the higher toll in recent years. The 2019-2020 season, which was shorter than normal, resulted in approximately 22,000 U.S. deaths. Globally, the number of annual flu deaths has been estimated to range from nearly 300,000 to more than 600,000. Results of a Phase II human influenza challenge study following vaccination with VXA-A1.1, which was funded by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), have previously been reported.2 Participants in the Phase II study received either VXA-A1.1, an injected quadrivalent, inactivated influenza vaccine (IIV) or a placebo. Participants were challenged with H1N1 influenza virus 90-120 days after vaccination and were monitored for signs and symptoms of infection and viral shedding. Results of the Phase II study were the first to show that VXA-A1.1 offered greater protection against viral shedding than the injected IIV. The results suggested that cellular responses rather than neutralizing antibodies may be especially important in the VXA-A1.1 mechanism of protection. The study announced on November 18, 2021 is the first to use mass cytometry to evaluate more than 40 different immune cell parameters in peripheral blood samples collected from 141 participants in the Phase II study. Mass cytometry immune cell profiling was performed on samples collected immediately prior to (day 1) and seven days following (day 8) vaccine administration. Immune profiling tracked levels of multiple cell subsets with similar patterns of markers. The relationship between each subset and virus shedding was determined. Random forest-based machine learning models were used to define high-dimensional cellular correlates between the immune profiling and viral shedding data. Key findings from the study include: Specific B cell and T cell responses contribute to protection from viral shedding with VXA-A1.1 but not with IIV. At day 8, vaccine-elicited subsets of plasmablasts (including a4ß7+, CD62L-, pSTAT5+ cells) and hemagglutinin (HA+)-specific cells significantly correlated with protection from viral shedding after day 90 in participants vaccinated with VXA-A1.1, but not in participants treated with IIV or placebo. At day 8, VXA-A1.1, but not IIV or placebo, elicited subsets of T cells expressing markers (ß7 integrin and CCR9) that are indicative of enhanced homing to mucosal tissue. Random forest models of the VXA-A1.1-treated group could distinguish those individuals who were later protected versus those who remained susceptible to the virus using datasets from both unsupervised clustering approaches and manual gating (p= 0.00001).

Vaxart, Inc. Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases

2021-11-16 13:00:00

Vaxart, Inc. announced the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The study shows Vaxart’s COVID-19 oral vaccine candidate’s potential efficacy in preventing SARS-CoV-2 infection. The Hamster Challenge Study adds to the significant body of preclinical and clinical evidence Vaxart has amassed during the last two years supporting its belief that Vaxart’s room temperature oral tablet COVID-19 vaccine candidate, can be effective against SARS-CoV-2: A Hamster Transmission Study, conducted by Duke University and published in bioRxiv last month, demonstrated that the COVID-19 vaccine reduced the airborne transmission of SARS-CoV-2 virus in a hamster model. These results are consistent with those from Vaxart's Phase II human flu challenge study, which showed that Vaxart's oral tablet flu vaccine was better at reducing shedding than the injectable flu vaccine comparator. Vaxart’s Phase I results, released earlier this year, showed that the vaccine triggered multiple immune responses against SARS-CoV-2 antigens, including strong T-cell and IgA responses. Vaxart anticipates its Phase II clinical study to provide additional evidence regarding the potential impact and efficacy of the oral tablet COVID-19 vaccine. Initial data from that study is expected in First Quarter 2022. Key findings from the study include: All hamsters that received two doses of the oral vaccine demonstrated protection from COVID-19. Vaccinated hamsters had no significant loss of weight over the five days post challenge, while unvaccinated hamsters lost up to 10% of their body weight. Lung weight, which can be an indirect measure of lung inflammation, was significantly lower in double-vaccinated hamsters compared with unvaccinated animals. Five days post challenge, double-vaccinated hamsters had a greater than 4 log reduction in viral load and had no detectable infectious virus in their lungs.

Vaxart, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-11 21:01:00

Vaxart, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Cezar Andrei Floroiu, CEO, President, Principal Financial Officer & Director, James F. Cummings, Chief Medical Officer, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-11 21:01:00

Vaxart, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Cezar Andrei Floroiu, CEO, President, Principal Financial Officer & Director, James F. Cummings, Chief Medical Officer, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

2021-10-26 12:00:00

Vaxart, Inc. announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, the only Phase II trial of an oral tablet COVID-19 vaccine underway in the world. Vaxart expects to enroll 96 subjects at four sites in the United States in the first part of its Phase II trial. The U.S. trial will be followed by an international trial involving a larger pool of subjects. The U.S. portion of the trial will be a randomized open-label dose and age escalation lead-in segment in naïve and previously vaccinated subjects, to be followed by an international placebo-controlled efficacy trial. The full data set from the U.S. trial is expected in First Quarter 2022. Vaxart has recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants in parallel. This allowed the company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials planned to start in 2021, and to start manufacturing vaccines for its upcoming norovirus Phase II trials.

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Vaxart, Inc. Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

2021-10-06 12:00:00

Vaxart, Inc. announced?that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial. Vaxart expects to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19 naïve and mRNA vaccinated subjects, later this month. The company's Phase II COVID-19 program will also include countries outside of the United States, starting with a trial in India that is expected to begin later this year.

Vaxart, Inc Appoints James F. Cummings as Chief Medical Officer

2021-09-27 12:00:00

Vaxart, Inc. announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine, drug and diagnostics development. He joins Vaxart as the Company prepares to begin its Phase II clinical trials for COVID-19 with an oral tablet formulation. Dr. Cummings brings a 26-year career in the U.S. Army serving as Director of the Department of Defense's Global Emerging Infectious Surveillance and Response System (GEIS), with Biosurveillance Laboratories in 71 countries, Director of Translational Medicine & Regulated Activities for the Walter Reed Army Institute of Research (WRAIR), and Consultant to the Surgeon General for all medical research and development. Before joining Vaxart, Dr. Cummings served as President, Government and Public Health Solutions at Icon GPHS, the federal business unit of Icon PLC, a leading global Contract Research Organization (CRO), and Vice President of Clinical Development and Translational Medicine at Novavax. He joined Vaxart earlier this month.

Elsevier Inc., 15th Vaccine Congress, Oct 04, 2021 through Oct 06, 2021

2021-09-22 20:05:00

Elsevier Inc., 15th Vaccine Congress, Oct 04, 2021 through Oct 06, 2021.

Vaxart, Inc. Presents at 15th Vaccine Congress, Oct-05-2021 06:00 AM

2021-09-22 20:05:00

Vaxart, Inc. Presents at 15th Vaccine Congress, Oct-05-2021 06:00 AM. Speakers: Susan Johnson, senior scientists.

Vaxart, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 10:40 AM

2021-09-22 17:33:00

Vaxart, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 10:40 AM. Venue: New York, United States. Speakers: Cezar Andrei Floroiu, CEO, President, Principal Financial Officer & Director, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Vaxart, Inc. Enters into A Lease Agreement with Britannia Pointe Grand Limited Partnership

2021-09-21 20:19:00

On September 17, 2021, Vaxart, Inc. entered into a lease agreement with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership, pursuant to which the Company will have approximately 24,606 square feet of rentable space located at 170 Harbor Way, South San Francisco, California 94080. The Company is currently occupying the Harbor Way Premises pursuant to that certain sublease, dated November 13, 2020, between the Company and Vera Therapeutics, Inc., a Delaware corporation. Pursuant to the Britannia Lease Agreement, the Company will rent the Harbor Way Premises for a term of forty-two months, commencing on October 1, 2025, and expiring on March 31, 2029. The Company will pay monthly rent of $177,327.23, subject to yearly increases as specified in the Britannia Lease Agreement. On September 17, 2021, the Company entered into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc., a Maryland corporation. The Second Amendment amends the Lease Agreement, dated April 17, 2015, as amended by that certain First Amendment to Lease Agreement, dated September 17, 2019.

Vaxart, Inc. Enters into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc

2021-09-21 20:19:00

On September 17, 2021, Vaxart, Inc. entered into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc., a Maryland corporation. The Second Amendment amends the Lease Agreement, dated April 17, 2015, as amended by that certain First Amendment to Lease Agreement, dated September 17, 2019. Currently, the Company has 5,188 square feet of rentable space located at 290 Utah Avenue, South San Francisco, California 94080 (the “Existing Premises”). Effective as of April 1, 2022, the Second Amendment expands the above premises to include an additional 24,544 square feet located at 310 Utah Avenue, South San Francisco, California 94080. The Second Amendment also extends the term of this lease until March 31, 2029.

Vaxart, Inc. Announces Board Appointments

2021-09-21 20:15:00

Vaxart, Inc. announced that it has formed a Manufacturing and Quality Advisory Board. The six leaders joining Vaxart's COVID-19 Manufacturing and Quality Advisory Board are John Aunins, Ph.D.; John Carpenter, Ph.D.; Benjamin Del Tito, Ph.D.; Vijay Jethwa, Ph.D.; Robert Schiff, Ph.D.; and Clifford Siporin, Ph.D.

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

2021-09-16 00:00:00

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million.

2021-09-13 00:00:00

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 13,932,490 Price\Range: $9.574742 Transaction Features: At the Market Offering

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million.

2021-09-13 00:00:00

Vaxart, Inc. has completed a Follow-on Equity Offering in the amount of $133.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 13,932,490 Price\Range: $9.574742 Transaction Features: At the Market Offering

Vaxart, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-07 20:20:00

Vaxart, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Andrei Floroiu, President and CEO, Sean N. Tucker, Senior VP & Chief Scientific Officer.

Vaxart, Inc. Appoints Julie M. Cherrington to the Board of Directors

2021-08-23 20:23:00

On August 20, 2021, the Board of Directors of Vaxart, Inc. appointed Julie M. Cherrington, Ph.D., to serve on the Board until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal. The Board has determined that Dr. Cherrington meets the requirements for independence under the applicable listing standards of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. Dr. Cherrington was also appointed as a member of the Audit Committee of the Board (the “Audit Committee”). Dr. Cherrington, 63, has served since September 2020 as the Chief Executive Officer of QUE Oncology (“QUE”), a clinical stage company developing novel non-hormonal treatments for vasomotor symptoms in postmenopausal women and cancer patients receiving hormone therapy.

Vaxart, Inc. Announces the Creation of an Eight-Member Scientific and Clinical Advisory Board

2021-08-19 20:02:00

Vaxart, Inc. announced the creation of an eight-member Scientific and Clinical Advisory Board. The Advisory Board, whose first meeting occurred on July 24, 2021, is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases. The eight leaders joining Vaxart'sScientific and Clinical Advisory Board are: Ralph Baric, Ph.D., is a Distinguished Professor in the Department of Epidemiology and a Professor in the Department of Microbiology and Immunology. In addition, he is a World Technology Award Finalist and a fellow of the American Association for Microbiology. He has spent the past three decades as a world leader in the study of coronaviruses and is responsible for UNC-Chapel Hill's world leadership in coronavirus research. The Baric Lab uses coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence, pathogenesis, genetics, and cross-species transmission. He has used alphavirus vaccine vectors to develop novel candidate vaccines. Robert Belshe, M.D., directed the NIH-funded Vaccine and Treatment Evaluation Unit (VTEU) at St. Louis University for the past three decades. His clinical and laboratory research interests include the development of live attenuated respiratory virus vaccines. Recent clinical projects include the evaluation of novel vaccines for influenza, including the live attenuated influenza vaccine available for children and adults aged 2-49. Belshe coordinated 50 other academic centers to evaluate a subunit vaccine for HSV2 in women ages 18-30. More than 8,300 women participated in the trial. Stefan Gravenstein, M.D., is a professor in the departments of Medicine and Health Services Policy and Practice at Brown University's schools of medicine and public health and serves as the Director of the Division of Geriatrics and Palliative Medicine at the Alpert Medical School of Brown University. Gregory C. Gray, M.D., MPH, FIDSA is an infectious disease epidemiologist and Professor at Duke University with three affiliations: The Division of Infectious Diseases in Duke University's School of Medicine, the Duke Global Health Institute, and the Duke Nicholas School of the Environment. He also serves as a Professor in the Program in Emerging Infectious Diseases and the Global Health Institute at Duke-NUS Medical School, Singapore, and as a Professor of Global Health at Duke Kunshan University in China. Harry B. Greenberg, M.D., the Joseph D. Grant Professor in the School of Medicine and Associate Dean for Research at Stanford University was the lead inventor of the first-generation vaccine for rotavirus, a severe diarrheal disease that kills between 300,000 and 400,000 children each year in the developing world. Marion Pepper graduated with a bachelor's degree in Biology and English from Williams College and received her Ph.D. in Immunology in 2006 from the University of Pennsylvania. She completed postdoctoral training at the University of Minnesota and joined the Department of Immunology as an Assistant Professor in 2011, and was promoted to Associate Professor 2017. Stanley A. Plotkin, M.D., is an Emeritus Professor at the University of Pennsylvania and an Adjunct Professor at Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute, and at the same time, Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. In 1991, Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught, where for seven years he was the Medical and Scientific Director, based at Marnes-la-Coquette, now known as Sanofi Pasteur. George R. Siber, M.D., is an internationally recognized vaccine expert with 40 years of experience in developing numerous innovative vaccines. From 1975 to 1996, Dr. Siber served on the Faculty of Medicine at Harvard University as Assistant and Associate Professor of Medicine based at the Dana Farber Cancer Institute. Concurrently, from 1982 to 1996, Dr. Siber was Director of the Massachusetts Biologic Laboratories. Under his leadership, the laboratory developed specific immune globulins to CMV (Cytogam) and to RSV (Respigam) the precursor product to Synagis.

Vaxart, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:40 PM

2021-08-18 15:33:00

Vaxart, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:40 PM. Venue: Loews Coronado Bay Resort, San Diego, California, United States. Speakers: Sean N. Tucker, Senior VP & Chief Scientific Officer.

Vaxart, Inc. Announces FDA Clearance IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

2021-08-02 12:00:00

Vaxart, Inc. announced that the U.S. Food and Drug Administration has cleared Vaxart's Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. Vaxart announced in February that it had completed a Phase 1 clinical trial for its oral S+N COVID-19 vaccine.  The results from that study found that the investigational oral vaccine triggered multiple immune responses against SARS-CoV-2 antigens, while reaching primary and secondary endpoints of safety and immunogenicity, respectively.

Vaxart, Inc. Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

2021-07-29 12:22:00

Vaxart, Inc. announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. Vaxart is a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection. Vaxart's programs are based on its proprietary oral vaccine platform called VAAST. The data came from Vaxart's 12-subject Phase 1b blinded study evaluating the ability of its norovirus vaccine to boost immunogenicity. Study participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021. All seven participants who had been?previously immunized with the oral norovirus vaccine elicited?a?similar?broad range of?immune responses?to norovirus as the five subjects that had not received a prior oral vaccine dose.?? Key metrics identified in the boosting study were as follows: Serum antibody blocking titer 50,?a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts. Antibody?secreting B cell (ASC) responses to norovirus VP1 measured?seven days post-boost were no different than?those in subjects receiving the vaccine for the first time. Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between subjects that had received a prior oral norovirus vaccine?and those who had not previously been vaccinated.

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.

Vaxart, Inc. Announces Auditor Changes

2021-07-20 10:05:00

On July 15, 2021, Vaxart, Inc. was notified that OUM & Co. LLP, an independent registered public accounting firm, had combined its practice with that of WithumSmith+Brown, PC and that the name of the combined practice will be WithumSmith+Brown." On July 16, 2021, OUM resigned as the auditors of the Company and the Audit Committee of the Company's Board of Directors engaged Withum to serve as the Company's new independent registered public accounting firm.

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for Its Vapendavir Antiviral Asset

2021-07-07 12:00:00

Vaxart, Inc. announced that it has signed an exclusive worldwide licensing agreement with Altesa Biosciences, Inc. to allow Altesa to develop and commercialize Vaxart’s patented formulation of the capsid-binding VapendavirTM, a clinical stage broad spectrum antiviral. Altesa is a clinical-stage pharmaceutical company developing therapeutics addressing RNA viruses, the principal cause of global infectious disease burden. Altesa was co-founded by Dennis Liotta, PhD, Executive Director of the Emory Institute for Drug Development and Samuel Candler Dobbs Professor of Chemistry at Emory University, and George Painter, PhD, a renowned biotech entrepreneur and co-founder of Drug Innovation Ventures at Emory (DRIVE), a university-based drug discovery center established in response to the falling output and rising costs of pharmaceutical research and development. Dr. Painter is the Chief Science Officer of Altesa and Dr. Liotta serves as chairman of Altesa’s Scientific Advisory Board. Under the terms of the agreement, Altesa is granted the worldwide, exclusive right to develop, manufacture, and commercialize Vaxart’s proprietary formulation of Vapendavir. Vaxart is eligible to receive up to $130 million in development and commercial milestones, as well as tiered royalties ranging from the low-single to low-double digits on product sales for multiple indications. Vaxart acquired Vapendavir in 2018 as part of the merger with Aviragen Therapeutics, Inc., and previously demonstrated preclinically and in clinical trials that Vapendavir is active against a broad spectrum of enteroviruses and could combat respiratory infections produced by the human rhinovirus (HRV). Vapendavir has potential applications in treating a range of infections including: epidemic hand, foot and mouth disease (HFMD) that affects millions globally, particularly in developing countries; HRV infection in chronic obstructive pulmonary disease (COPD) patients; and several illnesses affecting children, including enteroviral infections, seasonal recurrent lower respiratory tract infection (LRTI) in preschoolers, and seasonal asthma exacerbation in school-age children.